SkinBioTherapeutics (SBTX) Given Corporate Rating at Northland Securities

Northland Securities reissued their corporate rating on shares of SkinBioTherapeutics (LON:SBTX) in a research report sent to investors on Monday.

LON SBTX opened at GBX 14.70 ($0.20) on Monday. SkinBioTherapeutics has a 12 month low of GBX 7.07 ($0.10) and a 12 month high of GBX 17.75 ($0.24).

About SkinBioTherapeutics

SkinBioTherapeutics PLC operates as a life science company that focuses on skin health. Its SkinBiotix platform could enhance the barrier effect of skin models, improve repair, and reduce bacterial load. The company intends to serves skin healthcare sectors in cosmetics, infection control, and eczema.

Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit